Pfizer Inc. (NYSE:PFE) stands at a critical juncture as the pharmaceutical giant attempts to offset looming patent expirations with promising clinical trial results and strategic acquisitions. The company’s recent Phase 3 success with its cancer drug Tukysa and entry into the anti-obesity market signal management’s efforts to rebuild growth, even as analysts project declining revenues through 2026.
The New York-based drugmaker faces a challenging transition period between 2026 and 2029, when several key products will lose patent protection. This loss of exclusivity period threatens to erode revenues at a time when the company is still working to replace income from its once-dominant COVID-19 franchise.
Pfizer reported significant progress in December 2025 with its HER2CLIMB-05 Phase 3 study, which evaluated Tukysa (tucatinib) for HER2-positive metastatic breast cancer. The trial demonstrated an approximate 8.5-month benefit in progression-free survival.
The company has deployed capital from COVID-19 profits to fund acquisitions like Metsera, marking its re-entry into the high-growth anti-obesity market. These moves aim to address the revenue gap created by patent expirations.
Financial projections show a declining revenue trajectory, with FY2025 expected at $62.7B. EPS remains relatively stable due to cost restructuring. The dividend yields 6.8%, supported by net debt of $10.1B.
Valuation metrics suggest a discount, with P/E ratios around 8x. This reflects investor concerns about the patent cliff. However, cost savings of $7B by 2027 and strong oncology growth (5%) offer offsets.
Analyst opinions diverge. BMO Capital Markets rates Outperform with a $30 target. Citi Research rates Neutral with a $26 target, balancing operational efficiencies against medium-term challenges.
In summary, Pfizer offers a compelling value play with a high dividend, but faces significant risks from patent losses and competition.
